Pfizer says it eventually will pursue an OTC switch for the cholesterol drug Lipitor, but only after maximizing Rx revenues from the blockbuster product.
During Pfizer’s fiscal 2011 third-quarter earnings call Nov. 1, CEO Ian Read and other executives answered questions about the firm’s...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?